SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
There is an unmet medical need for potent ART regimens that make adherence to treatment even
easier due to QD dosing, offer a good tolerability profile and fit into the daily life of
patients.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination